Calcium2026-06

Denosumab increased bone mineral density but caused marked serum calcium fluctuations in a patient undergoing peritoneal dialysis.

Yamada Shunsuke, Enomoto Soma, Matsuo Kana, Sonezaki Yusuke et al. — CEN case reports

Summary

A medication called denosumab can strengthen bones in people with advanced kidney disease who are on peritoneal dialysis. However, this study shows that it can also lead to significant and rapid changes in blood calcium levels, both too low and too high. This highlights the need for very close monitoring and careful management of calcium for these patients.

AI-generated summary — read the original

Key points

Denosumab can improve bone strength in peritoneal dialysis patients with osteoporosis.
However, it can cause significant and rapid shifts in blood calcium levels.
Patients may experience both dangerously low and excessively high calcium levels after treatment.
Close monitoring and careful adjustment of calcium-related medications are crucial for these patients.

What the study looked at

The study explored the effects of a bone-strengthening medication, denosumab, on bone density and calcium levels in a patient undergoing peritoneal dialysis for advanced kidney disease. It aimed to understand the challenges of managing calcium balance in this specific patient group when using this drug. This was a case study focusing on one 56-year-old woman with end-stage kidney disease and osteoporosis who was receiving peritoneal dialysis. Researchers observed her bone density changes and closely tracked her blood calcium levels after she received a dose of denosumab. They also documented the adjustments made to her dialysis fluid and other calcium-related medications. The study found that denosumab successfully increased the patient's bone density. However, it also led to severe fluctuations in her blood calcium, first dropping dangerously low and then rising too high, despite efforts to prevent these changes. This highlights the complex challenge of managing calcium in dialysis patients treated with denosumab, emphasizing the need for very careful and frequent monitoring.

Dietary takeaway

For individuals with advanced kidney disease, especially those on dialysis, maintaining proper calcium levels is already a delicate balance. If you are prescribed denosumab for osteoporosis, it's crucial to discuss with your doctor how your calcium levels will be monitored and managed, as this medication can significantly impact them. Remember, this is a single case study, and while it offers important insights, it doesn't represent all patients or provide definitive guidance for everyone.

Abstract

Denosumab is increasingly used to treat osteoporosis in patients with advanced kidney disease, but clinically significant disturbances in calcium homeostasis remain a major concern. We report a peritoneal dialysis (PD) case in which denosumab administration was followed by pronounced calcium fluctuations requiring medication management. A 56-year-old woman with end-stage kidney disease due to lupus nephritis, receiving prednisolone (5 mg/day), had been on continuous ambulatory PD (1.5-L exchanges three times daily) for 5 years. Baseline intact parathyroid hormone was 176 pg/mL. Osteoporosis was confirmed by dual-energy X-ray absorptiometry (lumbar spine 68% and femoral neck 58% of the young adult mean [YAM]). Denosumab 60 mg was administered, and BMD increased within 10 months to 78% YAM at the lumbar spine and 77% YAM at the femoral neck (same facility, identical DXA equipment). To mitigate hypocalcemia, dialysate calcium was pre-emptively increased to two 3.5-mEq/L and one 2.5-mEq/L bags per day (albumin-corrected calcium 9.5 mg/dL at dosing). Nonetheless, symptomatic hypocalcemia developed (nadir 7.8 mg/dL on day 7), prompting escalation to three 3.5-mEq/L bags with intensified vitamin D therapy and calcium supplementation. Serum calcium then overshot, peaking at 13.8 mg/dL on day 29; therapy was de-escalated and calcium stabilized. This case highlights that while daily dialysate calcium exposure in PD may buffer early hypocalcemia, concurrent escalation of dialysate calcium, vitamin D therapy, and calcium supplementation can precipitate overshoot hypercalcemia. Frequent monitoring and staged, stepwise prescription changes during the first month after denosumab are essential. Standardized PD-specific post-denosumab calcium management protocols are urgently needed.

View on PubMed →DOI: 10.1007/s13730-026-01142-1